E1912: Median OS was not reached in either arm1

OS with median follow-up of 49 months1

Overall survival (secondary endpoint)2

IMBRUVICA® (ibrutinib) E1912 OS graph in patients with CLL/SLL

Abbreviations

CI=confidence interval, FCR=fludarabine, cyclophosphamide, rituximab, HR=hazard ratio, IR=IMBRUVICA® + rituximab, OS=overall survival.

References

1IMBRUVICA® (ibrutinib) Prescribing Information. 2Data on file ABVRRTI77313